Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. on May 10, 2022. The report details a corporate governance change involving the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
The primary material change reported is the increase in the authorized number of directors on the Board from seven to eight. Consequently, a vacancy was created and filled with the appointment of Jill O'Donnell-Tormey, Ph.D., effective May 18, 2022.
Management Commentary and Compensation
- Appointment Details: Dr. O'Donnell-Tormey was appointed as a Class II director with a term expiring at the 2025 annual meeting. She will serve as a member of the Nominating Committee.
- Background: She is the CEO and Director of Scientific Affairs of the Cancer Research Institute (CRI), a role she has held since 1993.
- Compensation: As a non-employee director, she will receive an annual cash retainer of $50,000.
- Equity Grant: She will receive an option to purchase 54,000 shares of common stock under the 2014 Equity Incentive Award Plan. The exercise price equals the closing price on the effective date of appointment. The option vests in substantially equal monthly installments over three years.
- Indemnification: The Company expects to enter into a standard indemnification agreement with Dr. O'Donnell-Tormey.
Investor Verification Checklist
- Verify the effective date of the appointment (May 18, 2022) and the term expiration (2025 annual meeting).
- Confirm the total equity grant size (54,000 shares) and the three-year vesting schedule.
- Review the Company's non-employee director compensation policy for any additional benefits not explicitly detailed in this summary.
- Check for any potential conflicts of interest given Dr. O'Donnell-Tormey's leadership role at the Cancer Research Institute.